Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population

References

• Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J.28(1), 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes; estimates for year 2000 and projections for 2030. Diabetes Care21(5), 1047–1053 (2004).
   Google Scholar
• Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Cardiovascular risk factors in Spanish population: meta-analysis of cross-sectional studies. Med. Clin. (Barc.)124(16), 606–612 (2005).
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann. Intern. Med.125(4), 304–310 (1996).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21(6), 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J. Clin. Hypertens.9(5), 324–329 (2007).
   PubMedGoogle Scholar
• Escobar C, Barrios V, Calderón A et al. Diabetes mellitus in hypertensive population attended in Primary Care in Spain. Blood pressure and lipid control rates. Rev. Clin. Esp.207(5), 221–227 (2007).
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch. Intern. Med.165(12), 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet355(9200), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet370(9590), 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med.342(25), 1887–1892 (2000).
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med.167(1), 68–73 (2007).
   PubMedGoogle Scholar
• Barrios V, Escobar C, Calderón A et al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens.21(6), 479–485 (2007).
   PubMed Web of Science ®Google Scholar
• Cifkova R, Erdine S, Fagard R et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J. Hypertens.21(10), 1779–1786 (2003).
   PubMedGoogle Scholar
• Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderón A. Lercanidipine is an effective and well tolerated antihypertensive drug regardless of the cardiovascular risk profile. The LAURA study. Int. J. Clin. Pract.60(11), 1364–1370 (2006).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Divison JA, Medialdea F. Clinical experience with a low-dose fixed combination of perindopril plus indapamide in a primary care setting. Findings from the PRETEND study. Therapy4(5), 677–683 (2008).
   Google Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension37(4), 1053–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Myers MG, Leenen FH. The impact of one or two missed doses on the duration of action of combined perindopril and indapamide. J. Hum. Hypertens.21(1), 86–93 (2007).
   PubMedGoogle Scholar
• Holland N, Segraves D, Nnadi VO et al. Identifying barriers to hypertension care: implications for quality improvement initiatives. Dis. Manag.11(2), 71–77 (2008).
   PubMedGoogle Scholar
• Vinker S, Alkalay A, Hoffman RD et al. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin. Pharmacother.9(8), 1271–1277 (2008).
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs62(3), 443–462 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Gosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens.23(11), 2063–2070 (2005).
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Viberti G, Halimi S et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Hypertension41(5), 1063–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Mallion JM, Chamontin B, Asmar R et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am. J. Hypertens.17(3), 245–251 (2004).
   PubMed Web of Science ®Google Scholar
• Laurent S. Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage. J. Hypertens. Suppl.21(3), 11–18 (2003).
   Google Scholar
• de Luca N, Asmar RG, London GM, O’Rourke MF, Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J. Hypertens.22(8), 1623–1630 (2004).
   PubMed Web of Science ®Google Scholar
• London GM, Asmar RG, O’Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J. Am. Coll. Cardiol.43(1), 92–99 (2004).
   PubMed Web of Science ®Google Scholar